{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triptan&page=2",
    "query": {
      "intervention": "Triptan",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triptan&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T10:56:26.281Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00337987",
      "title": "A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral T-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ontak",
          "type": "DRUG"
        },
        {
          "name": "CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2005-11",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2015-02-27",
      "last_synced_at": "2026-09-08T10:56:26.281Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00337987"
    },
    {
      "nct_id": "NCT01542255",
      "title": "Metronomic Therapy in Patients With Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "vinblastine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2010-06",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-09-08T10:56:26.281Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01542255"
    },
    {
      "nct_id": "NCT00354393",
      "title": "Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine ditartrate",
          "type": "DRUG"
        },
        {
          "name": "Adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Neoadjuvant Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "3-dimensional conformal radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Intensity-modulated radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2002-08",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2025-07-15",
      "last_synced_at": "2026-09-08T10:56:26.281Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00354393"
    },
    {
      "nct_id": "NCT00005047",
      "title": "4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "vinblastine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 521,
      "start_date": "1997-08",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-06-08",
      "last_synced_at": "2026-09-08T10:56:26.281Z",
      "location_count": 73,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 47 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Greeley",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005047"
    },
    {
      "nct_id": "NCT05557643",
      "title": "PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Depression",
        "Burnout, Professional"
      ],
      "interventions": [
        {
          "name": "Psilocybin",
          "type": "DRUG"
        },
        {
          "name": "Mindfulness-Based Stress Reduction (MBSR)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2023-01-02",
      "completion_date": "2024-09-20",
      "has_results": false,
      "last_update_posted_date": "2024-11-12",
      "last_synced_at": "2026-09-08T10:56:26.281Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05557643"
    },
    {
      "nct_id": "NCT04199026",
      "title": "Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Sarcoma",
        "Recurrent Sarcoma",
        "Resectable Sarcoma"
      ],
      "interventions": [
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Drug Delivery Microdevice",
          "type": "DEVICE"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Ganitumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Polyethylene Glycol",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-02-25",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-08T10:56:26.281Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04199026"
    },
    {
      "nct_id": "NCT07607938",
      "title": "Psilocybin as a Novel Therapy for Residual Anhedonia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anhedonia",
        "Emotional Blunting"
      ],
      "interventions": [
        {
          "name": "Psilocybin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 90,
      "start_date": "2026-09",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-09-08T10:56:26.281Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07607938"
    },
    {
      "nct_id": "NCT04982796",
      "title": "Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Amphetamine-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Psilocybin",
          "type": "DRUG"
        },
        {
          "name": "Treatment-as-usual",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Portland VA Research Foundation, Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "25 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2022-07-07",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-09-08T10:56:26.281Z",
      "location_count": 1,
      "location_summary": "Vancouver, Washington",
      "locations": [
        {
          "city": "Vancouver",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04982796"
    },
    {
      "nct_id": "NCT03730194",
      "title": "A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Autism Spectrum Disorder",
        "Attention Deficit Hyperactivity Disorder",
        "Sleep Disturbance"
      ],
      "interventions": [
        {
          "name": "Melatonin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Bedtime Bank",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-05-31",
      "completion_date": "2021-11-01",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-09-08T10:56:26.281Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03730194"
    },
    {
      "nct_id": "NCT00058422",
      "title": "Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "darbepoetin alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "indium In 111 ibritumomab tiuxetan",
          "type": "RADIATION"
        },
        {
          "name": "yttrium Y 90 ibritumomab tiuxetan",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "60 Years to 120 Years"
      },
      "enrollment_count": 65,
      "start_date": "2003-02-10",
      "completion_date": "2019-11-14",
      "has_results": true,
      "last_update_posted_date": "2020-11-12",
      "last_synced_at": "2026-09-08T10:56:26.281Z",
      "location_count": 2,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00058422"
    }
  ]
}